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Abstract
Background
Poor adherence to antiretroviral drugs and viral resistance are the main drivers of treatment
failure in HIV-infected patients. In sub-Saharan Africa, avoidance of treatment failure on
second-line protease inhibitor therapy is critical as treatment options are limited.
Methods
In the prospective observational study of the Kilombero & Ulanga Antiretroviral Cohort in
rural Tanzania, we assessed virologic failure (viral load�1,000 copies/mL) and drug resis-
tance mutations in bio-banked plasma samples 6–12 months after initiation of a protease
inhibitor-based treatment regimen. Additionally, viral load was measured before start of pro-
tease inhibitor, a second time between 1–5 years after start, and at suspected treatment fail-
ure in patients with available bio-banked samples. We performed resistance testing if viral
load was�1000 copies/ml. Risk factors for virologic failure were analyzed using logistic
regression.
Results
In total, 252 patients were included; of those 56% were female and 21% children. Virologic
failure occurred 6–12 months after the start of a protease inhibitor in 26/199 (13.1%) of
adults and 7/53 of children (13.2%). The prevalence of virologic failure did not change over
time. Nucleoside reverse transcriptase inhibitors drug resistance mutation testing performed
at 6–12 months showed a positive signal in only 9/16 adults. No cases of resistance muta-
tions for protease inhibitors were seen at this time. In samples taken between 1–5 years pro-
tease inhibitor resistance was demonstrated in 2/7 adults. In adult samples before protease
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inhibitor start, resistance to nucleoside reverse transcriptase inhibitors was detected in 30/
41, and to non-nucleoside reverse-transcriptase inhibitors in 35/41 patients. In 15/16 pediat-
ric samples, resistance to both drug classes but not for protease inhibitors was present.
Conclusion
Our study confirms high early failure rates in adults and children treated with protease inhibi-
tors, even in the absence of protease inhibitors resistance mutations, suggesting an urgent
need for adherence support in this setting.
Introduction
In Tanzania, as in many other sub-Saharan African (SSA) countries, there has been a tremen-
dous increase in HIV care and treatment services over the past decade. This has reduced the
prevalence of HIV infection to 4.6% [1]. Since the launch of free antiretroviral therapy (ART) in
2004 by the National AIDS Control Program, the number of individuals on therapy has
increased from less than 5,000 people to one million in 2017 [2]. Although this is a positive devel-
opment, there is an increasing incidence of treatment failures on first-line ART regimens—
mostly with efavirenz or nevirapine combined with two nucleoside reverse transcriptase inhibi-
tors (NRTI) [3]. A Tanzanian study from 2006–2009 showed a virologic failure (VF) rate of
patients on first-line ART at 14.9% after a median of 26.1 months on therapy (interquartile
range (IQR) 16.6–35.2). In all patients with virologic failure, 75.7% showed drug resistance
mutations (DRM) to the backbone nucleoside analogues (NRTI) and to non-nucleoside reverse
transcriptase inhibitors (NNRTI) [4]. In a previous study from our cohort in rural southern Tan-
zania, the overall VF rate was 9% in patients failing on first-line ART with 81% demonstrating
DRM to NRTIs or NNRTIs [5].
Second-line treatment in Tanzania consists of a boosted protease inhibitor (bPI) combined
with two NRTI. Additionally, in young children, a bPI-based treatment is currently started as a
first-line therapy [3]. Children have a particularly high risk of virologic failure [6, 7], which
puts them in jeopardy of having a lack of effective treatment options in the future. Thus far,
several studies from SSA found that poor adherence rather than viral resistance is the main
driver of failure under bPI treatment [8–10]. Information on DRM to bPI is crucial for future
treatment guidelines, however only limited data is available from SSA.
In this study, we investigated the virologic outcome and development of DRM in HIV-1
infected adults and children on a bPI-containing regimen and identified risk factors for the
development of treatment failure in a large rural HIV cohort in Tanzania.
Materials and methods
Study setting and participants
The Chronic Diseases Clinic at St. Francis Referral Hospital, Ifakara, Tanzania enrolls HIV-
positive patients in a prospective cohort (Kilombero and Ulanga Antiretroviral Cohort (KIU-
LARCO)). Written informed consent was obtained from the patient or, if younger than 18
years, the caregiver. Since its conception in 2005, KIULARCO enrolled more than 10,000
HIV-infected patients. Demographic, clinical, and treatment information is collected 4 times
per year. Plasma is sampled twice yearly with storage in an onsite biobank. The cohort has
been described in detail in other publications [11, 12]. For this study, we included all patients,
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enrolled into KIULARCO from 2005–2016, who were started on bPI-based ART, and who had
a stored plasma sample taken 6–12 months after the start of treatment. We also used data from
those newly enrolled on bPI treatment with a plasma sample taken at 6–12 months after enrol-
ment. No routine viral monitoring was in place during the study period; however, the treating
physician upon suspected immunologic or clinical failure could order viral load testing.
Data collection
Data on demographics, clinical progression and ART was extracted from the KIULARCO elec-
tronic medical records. We recorded risk factors for treatment failure at the start of bPI treat-
ment; namely sex, age, VF on first-line ART defined as viral load (VL)�1,000 copies/mL,
advanced HIV disease (CD4 cells<200/μL and/or WHO stage III/IV), BMI (only in adults),
and self-reported non-adherence [4, 13]. VL was tested on samples stored 6–12 months after
bPI start (‘6–12 months sample’). If available, VL was additionally measured on samples taken
within 6 months prior to start of bPI (‘pre-bPI sample’). Furthermore, we determined patients’
VL in a sample from>12 months after initiation of bPI, and at the time of clinical or immuno-
logic treatment failure on bPI treatment (‘failure sample’). Resistance testing was carried out in
samples with a VL�1,000 copies/mL, if amplification was successful.
HIV quantification and analysis
Cell-free plasma was collected after centrifugation of EDTA blood at 1,900 rcf for 5 minutes
and stored at -20˚C until tested for VL, DRM or, after 2 weeks of being stored at -80˚C. HIV
RNA was extracted from 200 μL of plasma using the Pure Link Viral RNA/DNA Mini Kit
(Thermofisher Scientific, Allschwil, Switzerland), according to the manufacturer’s instruc-
tions. Viral RNA quantification was performed with a validated in-house protocol with the
Taqman qPCR Master Mix (Thermofisher) using the StepOneTM System (Thermofisher), with
a detection limit of 100 viral RNA copies/mL; details have been reported elsewhere (dx.doi.
org/10.17504/protocols.io.749hqz6) [14]. For all VLs above 1000 copies/mL, genotyping of
HIV-1 DRM was performed with a validated in-house protocol by population sequencing on
an ABI 3130 capillary genetic analyzer, using six primers covering protease and reverse tran-
scriptase [14]. HIV-1 drug resistance was interpreted according to the Stanford HIV Drug
Resistance Database algorithm, version 8.4 (http://hivdb.stanford.edu). All DRM conferring
high-level resistance were considered. CD4 cell counts were determined by flow cytometry
(FACS Calibur, BD Company, Franklin Lakes, New Jersey, USA or Partec Cyflow counter,
Partec GmbH, Germany).
Outcomes
The primary outcome was VF, defined as HIV-1 RNA levels�1000 copies/mL. The secondary
outcome was the prevalence of drug resistance in patients with VF, as per the Major HIV-1
DRM list [15].
Definitions
Baseline was defined as the time point of starting a bPI ART or, if already on bPI ART, at inclu-
sion into the cohort; variables and co-variates for risk factor analyses were considered up to 6
months before this date. Non-adherence was defined as missed at least one pill at any time dur-
ing the past 6 months. VL results between 100–1000 copies/mL were defined as low-level vire-
mia (LLV), whereas levels�1000 copies/mL where defined as VF. Advanced HIV disease was
defined as CD4 cells <200/μL and/or a clinical WHO stage III/IV.
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Ethical considerations
The study was conducted according the current version of the World Medical Association
Declaration of Helsinki. The KIULARCO study was approved by the Ifakara Health Institute
institutional review board (IHI/IRB/No 16–2006), the Health Research Ethics Review Com-
mittee of the National Institute for Medical Research of Tanzania (NIMR/HQ/R.8a/Vol. IX/
620), and the Ethical Review Board of the Canton of Basel, Switzerland.
Statistical analyses
Demographic factors were summarized using frequencies and percentages for categorical data
and medians and IQR for continuous data. Univariable and multivariable logistic regression
models were used to estimate the association between risk factors and VF at 6–12 months.
Non-linearity of the association with continuous variables was tested and modeled accord-
ingly. Results are presented as odds ratios with 95% confidence intervals. Statistical analyses
were performed using STATA 14 (StataCorpLP, College Station, TX, USA).
Results
Patient characteristics
Between 2005–2016, 584 participants of the KIULARCO cohort, received a bPI-based treat-
ment (Fig 1). Of these, 332 were not eligible for the following reasons: being on bPI for a dura-
tion of less than 6 months, being switched back to a non-bPI regimen before 6 months, or no
sample available 6–12 months after bPI start. Characteristics at the start of bPI treatment of the
eligible 252 patients (199 adults and 53 children) included in the final analysis are summarized
in Table 1. Out of 199 adults, 121 (60.8%) were female (2 were pregnant), median age and
BMI were 41 years (IQR 33–49), and 21.5 (IQR 19.1–23.5) respectively. An advanced WHO
stage (III/IV) was recorded in 105 (52.8%) patients. The median CD4 cell count was 163/μL
(IQR 71–276), and median time on ART before start of a bPI was 3.6 years (IQR 1.5–5.8). Out
of 53 children, 20 (37.7%) were female, median age was 8 years (IQR 5–10), 39 (73.6%) were in
WHO stage III/IV, and median CD4 cell count was 590/μL (IQR 250.0–940.5) with a median
time on first-line ART of 3.3 years (IQR 2–5.2).
The pre-bPI ART consisted of one NNRTI, mostly combined with zidovudine (69.9%),
stavudine (42.9%) or tenofovir (32.9%). Due to reasons such as phasing out of certain regi-
mens, adverse reactions, non-adherence, patient decision or stock-outs, many patients experi-
enced several changes in their first-line treatment (median 2 (IQR 1–4)) before the start of a
bPI-based treatment.
Eleven out of 199 (5.5%) adults and 7/53 (13.2%) children had already been prescribed a
bPI treatment at the time of enrolment into our clinic. In adults, this was due to previously sus-
pected treatment failure. In contrast, children were started directly on a bPI regimen, which
was based on new guidelines [3]. At the start of the bPI-based regimen, tenofovir was the most
commonly prescribed backbone drug (204 (81.0%)).
Reasons for prescribing a bPI-based regimen were immunologic failure in 127 patients
(50.4%), clinical failure in 20 patients (7.9%), or as VL testing was not routine in Tanzania at
the time of the study, suspected VF (107 patients (42.5%)).
Virologic outcome and prevalence of DRM
Adults. VF was diagnosed after 6–12 months from initiation of bPI in 26/199 (13.1%) and
LLV in 11/199 (5.5%) of adult patients (Table 2). In 16/26 (61.5%) patients with VF, DRM test-
ing was done and revealed NRTI DRM in 9/16 (56.3%), NNRTI DRM in 14/16 (87.5%) and no
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bPI DRM. In 129 available samples taken between 1–5 years after start of bPI (>12 months on
bPI), VF was diagnosed in 15 (11.6%) and LLV was present in 12 of the 129 patients (9.3%) at
a median of 753 days (IQR 573–1033). Prevalence of VF and LLV were stable over this time
period (S1 Fig). DRM testing from samples taken between 1–5 years after bPI therapy was
only available in 7/15 (46.7%) patients, revealing NNRTI DRM in all seven, while 4 had addi-
tionally NRTI DRM, and 2 had, beside NRTI and NNRTI DRM, also bPI DRM (Table 2).
We analyzed 144 ‘pre-bPI samples’ to know whether there were pre-existing DRM. Of
these, only 60 (41.7%) had confirmed VF and 14 (9.7%) had LLV. In the 41 sequences, avail-
able from samples before bPI start, 35 (85.4%) patients had NNRTI DRM and 30 patients
(73.2%) had NRTI DRM. No bPI DRM was documented.
While on bPI treatment, 45 patients developed clinical or immunologic failure and had an
additional sample stored. Of these, we found VF in 11 (24.4%) patients. Among the 6 available
sequences all harbored NNRTI DRM, 3 harbored NRTI DRM, but no bPI DRM was observed. In
patients with sequential samples available, mostly NNRTI and NRTI DRM were detected during
all time points. Median time from start of bPI to diagnosed failure was 224 days (IQR 115–381).
Children. At 6–12 months, 7/53 (13.2%) children experienced VF and 4 (7.5%) had LLV.
Sequencing was successful in only 1 out of 7 and no DRM were detected. In 35 children, sam-
ples taken between 1–5 years after bPI therapy (>12 months on bPI), showed that 4 (11.4%)
had VF and 3 (8.6%) had LLV after a median of 581 days (IQR 467–743). Sequencing was suc-
cessful in 3 of those, yielding 1 patient with NRTI and NNRTI DRM, but no bPI DRM.
In the 41 analyzed samples prior to therapy with bPI, 19 (46.3%) showed evidence of VF.
After switching to bPI 16/19 re-suppressed, while 3 still had a VL >1000copies/mL. Two addi-
tional patients were suppressed before switch and experienced VF only in the 6–12 months
sample. In the 16 pre-bPI samples with diagnosed VF, sequencing provided evidence of resis-
tance with NRTI and NNRTI DRM in 15/16 (93.8%).
At the time of suspected clinical/immunologic failure on bPI, 2/10 (20.0%) had a positive
VL in the range of LLV, but none had a documented VF. Median time to diagnosed failure
was 93.5 days (IQR 82–179) in children.
Fig 1. Overview of available samples from included patients. Profile of the study cohort on second-line at the
Chronic Disease Clinic Ifakara in Ifakara, Morogoro, Tanzania. (KIULARCO Kilombero and Ulanga Antiretroviral
Cohort; bPI boosted Protease Inhibitors; FUP follow-up).
https://doi.org/10.1371/journal.pone.0227600.g001
High failure rates of protease inhibitor-based antiretroviral treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0227600 January 13, 2020 5 / 13
Prevalence of HIV subtypes
In our study population (85 available sequences from 75 patients) subtype C was most preva-
lent (35 isolates, 46.7%), followed by subtype A (23 isolates, 30.7%) and subtype D (9 isolates,
12%). This correlates well with the previously reported subtype distribution for the region
[14]. Recombinant HIV-1 forms were identified in 8 samples, 7 of subtypes C and D, including
CRF10_CD, and 1 of B/D.
Table 1. Patient’s characteristics at start of a boosted protease inhibitora.
Adults Children Overall
n 199 53 252
Female sex, n (%) 121 (60.8) 20 (37.7) 141 (56.0)
Age, median years (IQR) 41 (33–49) 8 (5–10) 36 (16–46)
Current pregnancy or delivery <3 months before start bPI, n
(%)
2 (1.0) - 2 (0.8)
Functional status, n (%)
- Working 174 (87.4) 50 (94.3) 224 (88.9)
- Ambulatory 17 (8.5) 3 (5.7) 20 (7.9)
- Bedridden 1 (0.5) 0 (0.0) 1 (0.4)
BMI (kg/m2), median (IQR) 21.5 (19.1–
23.5)
- 21.5 (19.1–
23.5)
WHO clinical stage, n (%)
- I/II 80 (40.2) 14 (26.4) 94 (37.3)
- III/IV 105 (52.8) 39 (73.6) 144 (57.1)
CD4 cell count/mm3, median (IQR) 163 (71–276.0) 590 (250–
940)
205 (84–364)
- Missing values, n (%) 46 (23.1) 9 (17.0) 55 (21.8)
Years on 1st line ART, median (IQR) 3.6 (1.5–5.8) 3.3 (2–5.2) 3.4 (1.6–5.8)
bPI based therapy at baseline 11 (5.5) 7 (13.2) 18 (7.1)
NRTI-backbone used during NNRTI-based ARTb,d, n (%)
- ZDV 133 (66.8) 41 (77.4) 174 (69.0)
- d4T 86 (43.2) 22 (41.5) 108 (42.9)
- TDF 78 (39.2) 4 (7.5) 82 (32.5)
Other (ddI, ABC) 3 (1.5) 4 (7.5) 7 (2.8)
NRTI-backbone used during bPI based ARTc,d, n (%)
- ZDV 63 (31.7) 9 (17.0) 72 (28.6)
- d4T 0 (0.0) 1 (1.9) 1 (0.4)
- TDF 166 (83.4) 38 (71.7) 204 (81.0)
- Other (ddI, ABC) 47 (23.6) 16 (30.2) 63 (25.0)
Reason for Start second-line, n (%)
- Suspected Clinical Failure 20 (10.1) 0 (0.0) 20 (7.9)
- Suspected Immunologic Failure 112 (56.3) 15 (28.3) 127 (50.4)
- Suspected Virologic Failure 67 (33.7) 40 (75.5) 107 (42.5)
a for patients registered on 2ndline treatment at enrolment
b all 1st line regimens contained 3TC/FTC additionally
c 94% of 2nd line regimens contained 3TC/FTC additionally
d frequent switches in backbone drugs due to variable availability
IQR interquartile range, bPI boosted protease inhibitor, BMI body mass index, ART antiretroviral treatment, NNRTI
Non-nucleoside reverse-transcriptase inhibitors, ZDV zidovudine, d4T stavudine, TDF tenofovir, ddI didanosine,
ABC abacavir, 3TC lamivudine, FTC emtricitabine
https://doi.org/10.1371/journal.pone.0227600.t001
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Mutational patterns of DRM
Overall, we found bPI DRM only in 2 adult patients. Both had been on a long-term bPI regi-
men (1027 and 1643 days, respectively) and both had accumulated multiple major bPI DRM.
The first of these patients had the following mutations: M46I, L76V, V82A and I84IV. The sec-
ond patient had L24I, M46I, I50L, I54A, and V82A.
The most common NNRTI mutation was K103NS, detected in 29 (51.8%) adults and 7
(36.8%) children. Additionally, Y181CIV was found in 15 (26.8%) and 4 (21.1%), E138KAQG
in 10 (17.9%) and 4 (21.1%) and G190ASEQ in 12 (21.4%) and 5 (26.3%) adults and children,
respectively.
For the NRTI, the most common non-TAM DRM was M184VI, which was found in 35
(62.5%) adults and 14 (73.7%) children. TAMs were found in 18 (32.1%) adults and 11 (57.9%)
in children (Table 3).
Adherence
Prior to starting bPI, 27/199 (13.5%) adults and 15/53 (28.3%) children had reported episodes
of non-adherence to ART intake. After 6–12 months on bPI, 19/199 (9.5%) adults and 9/53
(17.0%) children still reported non-adherence (S1 Table). Most common reasons for non-
adherence were ‘having lost’ or ‘run out of’ medication, reported in 9/42 (21.4%) cases on first-
line treatment and 11/28 (39.3%) on second-line treatment. One patient indicated depression
as a reason for not taking pills during first-line treatment (1/42; 2.4%) and one on second-line
(1/28; 3.6%). Reasons for poor adherence reported on first-line treatment only were ‘being too
Table 2. Virologic outcome of 656 samples in 252 patients at different time points.
Pre-bPI
-6-0 months
6–12 months 1–5 years Failure
on bPI
Adults (>15 years at start bPI)
Available samples, n 144 199 129 45
- Virologic Failure, n (%) 60 (41.7) 26 (13.1) 15 (11.6) 11 (24.4)
- Low-Level viremia, n (%) 14 (9.7) 11 (5.5) 12 (9.3) 0 (0.0)
- Undetectable viral load, n (%) 70 (48.6) 162 (81.4) 102 (79.1) 34 (75.6)
DRM, n/tested isolates� (%)
- NRTI 30/41(73.2) 9/16 (56.3) 4/7(57.1) 3/6(50.0)
- NNRTI 35/41(85.4) 14/16 (87.5) 7/7(100.0) 6/6(100.0)
- bPI 0/41(0.0) 0/16 (0.0) 2/7(28.6) 0/6 (0.0)
Children (<15 years at start bPI)
Available samples, n 41 53 35 10
- Virologic Failure, n (%) 19 (46.3) 7 (13.2) 4 (11.4) 0 (0.0)
- Low-Level viremia, n (%) 6 (14.6) 4 (7.5) 3 (8.6) 2 (20.0)
- Undetectable viral load, n (%) 16 (39.0) 42 (79.2) 28 (80.0) 8 (80.0)
DRM, n/tested isolates� (%)
- NRTI 15/16 (93.8) 0/1 (0.0) 1/3 (33.3) 0/0 (0.0)
- NNRTI 15/16 (93.8) 0/1 (0.0) 1/3 (33.3) 0/0 (0.0)
- bPI 0/16 (0.0) 0/1 (0.0) 0/3 (0.0) 0/0 (0.0)
bPI boosted protease inhibitor, DRM drug resistance mutation, NRTI Nucleoside Reverse Transcriptase Inhibitors, NNRTI Non-nucleoside reverse-transcriptase
inhibitors
� number of strains with resistance out of successfully genotyped HIV DRM among patients with a VL = 1000c/mL
https://doi.org/10.1371/journal.pone.0227600.t002
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ill or too healthy’ (3/42; 7.1%), ‘being concerned about stigma’ (2/42; 4.8%) and ‘problems
with delivery or stock out’ (1/42; 2.4%).
Risk factors for failing on second-line
For adults, the presence of advanced HIV disease (WHO stages III/IV or CD4<200) was the
only significant factor associated with a positive VL at 6–12 months on bPI (univariate analysis
Odds ratio 5.04; 95% confidence interval 1.15–22.15, p = 0.03). For children, none of the inves-
tigated factors was significantly associated with a positive VL (Table 4).
Discussion
In this cohort from rural SSA we found a high rate of virologic failure on a bPI-based regimen
despite a low emergence of resistance, which occurred exclusively after long-term drug expo-
sure to protease inhibitors.
At 13%, the failure rate in adults and children, occurring early on bPI-based therapy, was
higher than observed in the same cohort for patients on a long term first-line treatment, where
Table 3. Drug resistance mutations in patients with virologic failure.
HIV drug resistance
mutations
Number of adults with resistance testing at all
timepoints n = 56
Number of children with
mutations n = 19
NRTI-associated DRM n (%)
M184VI 35 (62.5) 14 (73.7)
K65R 9 (16.1) 0 (0.0)
K70E 0 (0.0) 1 (5.0)
L74VI 7 (12.5) 0 (0.0)
Y115F 2 (3.6) 0 (0.0)
V75M 4 (7.1) 0 (0.0)
TAM 18 (32.1) 11 (57.9)
NNRTI-associated DRM n (%)
L100I 3 (5.4) 0 (0.0)
K101PEH 5 (8.9) 3 (15.8)
K103NS 29 (51.8) 7 (36.8)
V106AM 8 (14.3) 1 (5.3)
E138KAQG 10 (17.9) 4 (21.1)
V179DEF 2 (3.6) 3 (15.8)
Y181CIV 15 (26.8) 4 (21.1)
Y188LCH 6 (10.7) 0 (0.0)
G190ASEQ 12 (21.4) 5 (26.3)
F227LC 0 (0.0) 1 (5.3)
bPI-associated DRM n (%)
L24I 1 (1.8) 0 (0.0)
M46I 2 (3.6) 0 (0.0)
I50L 1 (1.8) 0 (0.0)
I54A 1 (1.8) 0 (0.0)
L76V 1 (1.8) 0 (0.0)
V82A 2 (3.6) 0 (0.0)
I84IV 1 (1.8) 0 (0.0)
DRM drug resistance mutation, NRTI Nucleoside Reverse Transcriptase Inhibitors, NNRTI Non-nucleoside reverse-
transcriptase inhibitors, bPI boosted protease inhibitor
https://doi.org/10.1371/journal.pone.0227600.t003
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resistance remained stable over time [5]. Similar studies on virologic failure rates on bPI-based
treatment from other SSA settings report failure rates ranging from 11.1% [16] to 26% [17].
This trend was seen early after the start of bPI and remained stable over time. The high failure
rates might be due to an inadvertent selection of patients with poor adherence. This hypothesis
is supported by similar findings in other studies, which hardly found any viral resistance
against bPI [18, 19]. In children from the same cohort, virologic failure rates on bPI were
lower than the previously reported 25.4% on a first-line regimen [7]. A pediatric study from a
similar cohort in Lesotho reported failure rates (VL�80 copies/mL) of 28% on first-line treat-
ment and, despite counseling, of 49% after switching to bPI [6]. This data indicates key chal-
lenges in the management of HIV-infected children such as ART-acceptance and -tolerability,
inability to swallow the pills mainly designed for adults, and likely pharmacokinetic issues
[20].
The fact that HIV was suppressed on first-line treatment in about half of the patients with
suspected treatment failure, supports the earlier notion that clinical deterioration or immuno-
logic failure, based on the monitoring of CD4 cells and clinical condition alone, are poor pre-
dictors for VF [21, 22]. Possible reasons for an insufficient CD4 recovery other than an
ongoing HIV replication could reside in vitamin and nutritional deficiencies, drug toxicities
or alcohol intake. Interestingly, virologic failure rates were only 24.4% in adults with a diagno-
sis of clinical or immunologic failure on second-line treatment. This suggests that during sec-
ond-line treatment, even more clinical situations were misclassified as “suspected treatment
failures” than on first-line treatment, highlighting the need for routine viral monitoring, which
was implemented in Tanzania shortly after completion of this study.
Side effects of bPI, e.g. diarrhea, are likely to lead to poor adherence and consequent ongo-
ing virus replication, especially in those failing patients who had not previously failed on
NNRTIs. Furthermore, it is possible that patients were sensitized to adherence questions and
subsequently not admit to any poor adherence.
The high resistance rates for NNRTI in almost all virologically unsuppressed patients on
first- or second-line treatment confirms that DRM do accumulate with time. This occurs when
routine VL monitoring is not available and is a major concern with non-adherent patients,
who are at risk of acquiring bPI DRM. The generally low bPI-related resistance rates can be
Table 4. Risk factor analysis for virologic failure at 6–12 months on boosted protease inhibitor.
Univariable Multivariable
OR (95% CI) p-value OR (95% CI) p-value
Adults
Male sex 1.39 (0.61–3.19) 0.44 1.97 (0.73–5.34) 0.18
Age 0.99 (0.95–1.02) 0.46 0.98 (0.94–1.03) 0.41
Advanced HIV disease 5.04 (1.15–22.15) 0.03 6.95 (0.89–54.22) 0.06
BMI 0.97 (0.87–1.08) 0.55 0.98 (0.86–1.10) 0.71
Non-Adherence on bPI 1.38 (0.37–5.12) 0.64 1.54 (0.37–6.41) 0.55
Children
Male sex 4.23 (0.47–37.99) 0.20 3.06 (0.27–33.65) 0.36
Age 0.97 (0.80–1.20) 0.81 0.87 (0.62–1.21) 0.41
VF pre-bPI 1.87 (0.28–12.61) 0.51 1.94 (0.27–13.78) 0.51
Advanced HIV disease 2.12 (0.23–19.44) 0.51 0.85 (0.05–12.51) 0.91
OR odds ratio, CI confidence interval, BMI. Body mass index, bPI boosted protease inhibitor, VF virologic failure
RNA levels�1000 copies/mL; advanced HIV disease: either CD4 cells <200/μL and/or WHO stage III/IV.
https://doi.org/10.1371/journal.pone.0227600.t004
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attributed to the higher barrier to resistance development of this drug class [23] and the pre-
sumably lower time of exposure.
Our study confirms, in line with two other trials from SSA, that—even in the presence of
NRTI resistance mutations—a triple drug regimen can retain efficacy with no obvious inferi-
ority to other regimens [24, 25]. At the same time, our findings indicate that resistance through
emerging mutated viruses is probably not the only cause for second-line treatment failure.
However, this phenomenon is not fully understood.
It remains to be elucidated, whether resistance testing followed by guided treatment switch-
ing is beneficial, cost saving, and will reduce second-line treatment failures. Results of the
ongoing REVAMP study in South Africa are anticipated to address this question [26]. Resis-
tance data are urgently needed for defining optimal combinations of third-line drugs to be
rolled out in Tanzania and other countries in SSA in the near future.
In our study, we measured LLV in 52 samples. In recent years, more literature on the signif-
icance of LLV is emerging [27, 28]. A study from Lesotho has shown a high percentage of resis-
tance in these patients [29], challenging current guidelines, which classify only patients with a
VL�1000 copies/mL as failing. Thus, a significant number of patients with lower VL might
harbor resistance-associated mutations to the current regimen, increasing the risk for clinical
failure and onwards transmission of resistance.
The only factor associated with VF at 6–12 months in adults was advanced HIV disease at
the time of starting bPI. Factors such as an underlying untreated and progressing disease, asso-
ciated weakness affecting the ability to travel and to attend clinical visits, drug intake, drug
interactions, or side-effects of different medications leading to non-adherence could explain,
why people with advanced illness more often had VF [13, 30].
Currently, the knowledge about second-line failure in Tanzania is scarce. The strength of
this study is an even age distribution among those enrolled due inclusion of both children and
adults. Another strength is the long follow-up time with corresponding samples available from
different time points. Furthermore, this study adds resistance information, which is not avail-
able in many settings.
Our study has several limitations. The number of available samples of patients on bPI ART
was relatively low. This was due to a significant variability in sample quality which led to inabil-
ity to obtain sequencing results for every sample. This might have resulted in an underestima-
tion of the true prevalence of viral drug resistance. Moreover, VL testing was done from bio-
banked samples, and the definition of VF was based on a single VL, at the time neither con-
firmed by a second measurement nor followed by enhanced counseling, as recommended in
the current national and WHO guidelines [3]. Lastly, adherence through self-reporting provides
a rough estimate of pill intake. This practice in the absence of therapeutic drug monitoring may
lead to underestimation of poor adherence. Moreover, patients on bPI have already failed on a
first-line treatment, thus representing a selection of patients at higher risk for poor adherence.
In conclusion, we demonstrate that VF can occur early after the start of bPI, remaining sta-
ble over time and is best explained by poor adherence and less well indicated by overt drug
resistance mutations. High early failure rates with overall poor adherence are worrisome as
they may pave the way to further and accelerated resistance, clinical failure and higher rates of
viral transmission especially of drug-resistant HIV strains. Therefore, better monitoring tools
to improve adherence are urgently needed in rural settings.
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